ABSTRACT BACKGROUND: Pain relief, using opiates as a primary choice, is an important part of treating limb fractures. Yet, in order to reduce opiate consumption, other combinations have been introduced. This study aimed to compare pain reduction by a combination of morphine-midazolam with morphine injection in patients with limb fractures.
and severe pain. [5, 6] Such guidelines recommend the use of MS for patients with a pain score of 6 or higher on the visual analogue scale (VAS) until the pain is controlled (severity of pain reduced to 3 or lower).
Yet, using MS is limited by a variety of factors including fear of side effects, impairment of physical examination, and fear of addiction. [7] Furthermore, dose adjustment is required on a personal bases to achieve balance between pain control and these concerns. Recent evidence has pointed to the fact that MS is not as effective as once thought in ED patients. It has been suggested that within 15 minutes of administration, only 50% of the patients experience pain control. [4, 8, 9] Therefore, despite noticeable strides, pain control in the ED is still an unresolved issue. [3, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Consequently, researchers have proposed other drug regimens to reduce MS consumption in the ED. Combination drug therapy is one such regimen aiming to improve pain control whilst reducing MS use. [13] [14] [15] Midazolam is an imidazobenzodiazepine with unique characteristics. It acts faster than other drugs in this category and is a stronger sedative, hypnotic, and anxiolytic. These proper-
INTRODUCTION
Pain reduction of limb fracture patients in the emergency department (ED) is a treatment priority for the emergency physician. [1] [2] [3] Pain control is closely related to patient satisfaction. [2, 4] ties have led to its increased use in the ED, either as a sole drug or in combination with Fentanyl or Ketamine. The use of morphine-midazolam (M/M) combination in painful conditions is based on the well-known relationship between anxiety and pain. [16, 17] Despite animal studies suggesting the possibility of increased nociception with the use of midazolam, [18] the bulk of clinical studies have either reported better pain control, [16, 19, 20] or no significant effect. [21] [22] [23] This study aimed to compare M/M combination with MS in pain control of patients suffering from isolated traumatic fracture of extremities.
MATERIALS AND METHODS
This was a double-blind randomized clinical trial on patients aged 18 to 60 brought to the ED of our teaching hospital with isolated upper or lower extremity fractures. The study protocol was approved by the hospital ethical committee. The patients were randomly attributed to one of the two groups receiving either MS or M/M. With a confidence interval of 95% and a power of 90%, the required sample size was estimated to be 20 patients. Patients were included based on the following criteria: 18-60 years of age, isolated extremity fracture, and an initial pain score greater than 7 on verbal numerical rating scale (VNRS). Patients were excluded if they refused to participate, had history of allergies to opiates or benzodiazepines, if opiates had been used in pre-hospital setting, if there were any contraindications to opiate use (i.e. chronic respiratory failure, under treatment for opiate addiction), pregnancy or lactation, history of chronic pain, and if they were unable to determine the severity of pain (i.e. intoxication, dementia).
On arrival, the patient's pain level was determined by asking them to rate their pain on an 11-point (0-10) numerical rating scale. [24] Based on the randomization sheet, each patient was administered a prepared solution of either M/M (0.05 mg/ kg Morphine and 0.02 mg/kg Midazolam) or MS (0.05 mg/kg Morphine sulfate) intravenously. Patient pain scores and side effects were then re-measured at 15, 30, 45, 60, 120, and 180 minutes after drug administration. In order to reassure the study's double blind design, the preparation, administration, and recording of pain scores were performed by three different clinicians. If any adverse side-effects were recorded, the content of the injected solution was made available to the clinician and the patient was removed from the study. At 15 minutes, if the patient required further pain control, a rescue dose of the original combination with the same dosing was injected.
The data were analyzed using SPSS 11.5 and STATA 11.0 software. Pain scores on determined intervals were described using means and standard deviations and the difference between the two groups was tested using T-test. The effect of gender and site of injury on pain relief was tested using the Chi-Square test. Generalized Estimating Equations (GEE) were used to analyze the effects of difference in pain severity in both groups. Finally, the Kaplan-Meier plot was drawn to describe and compare success between the two groups within the first 3 hours. A 50% or more reduction in pain severity was considered successful pain control and a p-value of less than 0.05 was considered significant.
RESULTS
A total of seventy-two patients were included into the study, 36 being in each group. The demographics and initial pain scores are summarized in Table 1 . T-test and chi-square test were used to determine any significant differences between the two groups.
Administration of both MS and M/M significantly reduced pain in all time intervals (p<0.0001, df=13.2, F=109.7). There was also a significant trend towards pain reduction in both groups as time passed (p trend <0.0001). standard deviation of pain scores in each interval. GEE test failed to discover any significant difference in pain reduction between the two groups.
The Kaplan-Meier plot was drawn to demonstrate success rates in both groups. Any patient experiencing over 50% reduction in pain as compared to the initial score was calculated as a success. As demonstrated in Figure 1 , in the first 15 minutes after injection, MS and M/M achieved success in 8.3 and 11.1% of the cases, respectively. This number increased to 22.2 and 27.7% in the 30th minute, and then to 33.3 and 44.4% at the 45th minute. MS achieved success in 63.9, 88.9, and 100% of the group by the first, second, and third hour, respectively. On the other hand, M/M achieve 63.8 and 91.7% in the first and second hours while by the third hour it failed to control pain in only one patient. A rescue dose also failed to achieve success in this patient. The Log-rand test failed to recognize any significant difference in success rate or trend within the two groups (p=0.55).
DISCUSSION
This clinical trial showed that M/M combination was not superior to MS for relieving the pain of isolated limb fractures.
MS has a proven role in pain control established in different settings. [4, 7, 10, 21] Yet, due to its adverse effects and problems in determining the effective dose, researchers have turned to drug combinations. Galinski and colleagues have combined low-dose ketamine with morphine and have been able to reduce morphine requirements by 26%. [25] A possible role for targeting gamma-amino-butyric acid (GABA) receptors for pain control has been suggested. [26] Like other benzodiazepines, Midazolam is an agonist of benzodiazepine receptors acting on GABA receptors and facilitate the influx of chloride ions into neurons. The affinity of midazolam to these receptors is twice that of diazepam reflecting its increased potency. Midazolam is different from other benzodiazepines in its short half-life, multiple routes of administration, and better safety profile. [27] As a result, midazolam was our choice as a possible combination to morphine sulfate. Morphine works essentially in the medulla and reduces the conduction of signals within the pain pathway. [28] On the other hand, midazolam works in the cortex and increases the sensitivity of GABA receptors. [29] We hypothesized that combining these two drugs utilizing different mechanisms of action could be a more efficient approach to pain control as opposed to morphine alone. This hypothesis has previously been reinforced by several studies. In 1996, Gilliland and colleagues studied the effects of bolus and continuous midazolam infusion on fifty patients undergoing elective hysterectomy. This placebo-controlled double-blind randomized controlled trial showed that during the first 12 hours after surgery, MS consumption was significantly lower in the midazolam group. [30] In 2000, while assessing postoperative anxiety, Kain et al. found that patients treated with midazolam 30 min before surgery reported a greater reduction in postoperative pain throughout the first postoperative week and patients reported less ibuprofen use. [16] In a recent study, Day and colleagues examined archival data from a parallel-group, double-blinded, placebo-controlled randomized controlled trial in which patients self-administered pain or anxiety medication. The researchers found that although there was no significant difference in pain scores, the treatment group used significantly less morphine than the control group and felt better. [19] On the other hand, several studies have questioned analgesic enhancement by midazolam. Wille-Ledon and colleagues have demonstrated a similar pain relief profile for Morphine and Morphine-Midazolam combination in the pediatric population with limb fractures. [21] More recently, Auffret et al. have studied the role of adding midazolam to MS in pre-hospital trauma patients. The study was a prospective randomized doubleblind placebo-controlled trial. Pain was assessed using a NRS and a difference of 3 points between the groups was considered significant effect. The study failed to find any benefit of midazolam adjunctive therapy to morphine in pain control. [23] To our knowledge, ours is the first study comparing M/M and MS in the setting of adult trauma patients in the emergency department. Like that of Wille-Ledon and Auffret, our results failed to prove an added analgesic effect when midazolam was added to morphine. In our study, patients in both groups showed a similar amount and trend in pain reduction and the success rate in both groups was comparable. Furthermore, our results showed that despite even using a rescue dose, more than half of the patients still suffered from significant pain 30 minutes after either MS or M/M injection, reflecting, to some extent, the unreliability of morphine in its initial dose and justifying the search for a more effective and reliable analgesic in limb fractures.
Limitations and Conclusion
This study was the first double-blind randomized control trial to compare the effects of M/M to MS for pain reduction in acute isolated limb fractures. Since the study was set in the emergency department, only short term results were sought and possible long-term outcomes derived from the combination therapy were not evaluated. A placebo group was not used for ethical concerns. Another limitation was homogeneity of the two groups. As seen in Table 1 , both groups were found to be significantly different regarding age (p=0.03). Taking into account the mean age of both groups, it is to our belief that this should not affect the interpretation of our findings. Results of the current study showed that adding midazolam to morphine did not improve its pain relieving characteristics in limb fractures.
